Oklahoma 2025 Regular Session

Oklahoma Senate Bill SB860 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1	1
2	2
3		-	ENGR. S. B. NO. 860 Page 1 1
	3	+	SENATE FLOOR VERSION - SB860 SFLR Page 1
	4	+	(Bold face denotes Committee Amendments) 1
4	5		2
5	6		3
6	7		4
7	8		5
8	9		6
9	10		7
10	11		8
11	12		9
12	13		10
13	14		11
14	15		12
15	16		13
16	17		14
17	18		15
18	19		16
19	20		17
20	21		18
21	22		19
22	23		20
23	24		21
24	25		22
25	26		23
26	27		24
27	28
28		-	~~ENGROSSED~~ SENATE
29		-	~~BILL NO.~~ ~~860 By: Weaver of the Senate~~
	29	+	SENATE FLOOR VERSION
	30	+	March 4, 2025
30	31
31		-	and
32	32
33		-	Kannady of the House
	33	+	COMMITTEE SUBSTITUTE
	34	+	FOR
	35	+	SENATE BILL NO. 860 By: Weaver
	36	+
34	37
35	38
36	39
37	40
38	41		An Act relating to the Uniform Controlled Dangerous
39	42		Substances Act; amending 63 O.S. 2021, Section 2 -204,
40	43		as last amended by Section 3, Chapter 308, O.S.L.
41	44		2024 (63 O.S. Supp. 2024, Section 2 -204), which
42	45		relates to Schedule I substances; adding certain
43	46		substance to Schedule I; and providing an effective
44	47		date.
45	48
46	49
47	50
48	51
49	52
50	53		BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
51	54		SECTION 1. AMENDATORY 63 O.S. 2021, Section 2 -204, as
52	55		last amended by Section 3, Chapter 308, O.S.L. 2024 (63 O.S. Supp.
53	56		2024, Section 2-204), is amended to read as follows:
54	57		Section 2-204. The controlled substances listed in this section
55	58		are included in Schedule I and incl ude any material, compound,
56	59		mixture, or preparation that contains any quantity of the following
57	60		hallucinogenic substances, their salts, isomers , and salts of
58	61		isomers, unless specifically excepted, when the existence of these
59	62		salts, isomers, and salts of isomers is possible within the specific
60	63		chemical designation.
61		-	A. Any of the following opiates including their isomers,
62		-	esters, ethers, salts, and salts of isomers, esters, and ethers,
63	64
64		-	ENGR. S. B. NO. 860 Page 2 1
	65	+	SENATE FLOOR VERSION - SB860 SFLR Page 2
	66	+	(Bold face denotes Committee Amendments) 1
65	67		2
66	68		3
67	69		4
68	70		5
69	71		6
70	72		7
71	73		8
72	74		9
73	75		10
74	76		11
75	77		12
76	78		13
77	79		14
78	80		15
79	81		16
80	82		17
81	83		18
82	84		19
83	85		20
84	86		21
85	87		22
86	88		23
87	89		24
88	90
	91	+	A. Any of the following opiates including their isomers,
	92	+	esters, ethers, salts, and salts of isomers, esters, and ethers,
89	93		unless specifically excepted, when the existence of these isomers,
90	94		esters, ethers, and salts is possible within the specific chemical
91	95		designation:
92	96		1. Acetylmethadol;
93	97		2. Allylprodine;
94	98		3. Alphacetylmethadol;
95	99		4. Alphameprodine;
96	100		5. Alphamethadol;
97	101		6. Benzethidine;
98	102		7. Betacetylmethadol;
99	103		8. Betameprodine;
100	104		9. Betamethadol;
101	105		10. Betaprodine;
102	106		11. Clonitazene;
103	107		12. Dextromoramide;
104	108		13. Dextrorphan (except its methyl ether);
105	109		14. Diampromide;
106	110		15. Diethylthiambutene;
107	111		16. Dimenoxadol;
108	112		17. Dimepheptanol;
109	113		18. Dimethylthiambutene;
110	114		19. Dioxaphetyl butyrate;
111		-	20. Dipipanone;
112		-	21. Ethylmethylthiambutene;
113	115
114		-	ENGR. S. B. NO. 860 Page 3 1
	116	+	SENATE FLOOR VERSION - SB860 SFLR Page 3
	117	+	(Bold face denotes Committee Amendments) 1
115	118		2
116	119		3
117	120		4
118	121		5
119	122		6
120	123		7
121	124		8
122	125		9
123	126		10
124	127		11
125	128		12
126	129		13
127	130		14
128	131		15
129	132		16
130	133		17
131	134		18
132	135		19
133	136		20
134	137		21
135	138		22
136	139		23
137	140		24
138	141
	142	+	20. Dipipanone;
	143	+	21. Ethylmethylthiambutene;
139	144		22. Etonitazene;
140	145		23. Etoxeridine;
141	146		24. Furethidine;
142	147		25. Hydroxypethidine;
143	148		26. Isotonitazene;
144	149		27. Ketobemidone;
145	150		28. Levomoramide;
146	151		29. Levophenacylmorphan;
147	152		30. Metonitazene;
148	153		31. Morpheridine;
149	154		32. N-desethyl isotonitazene;
150	155		33. N-pyrrolidino protonitazene;
151	156		34. Noracymethadol;
152	157		35. Norlevorphanol;
153	158		36. Normethadone;
154	159		37. Norpipanone;
155	160		38. Phenadoxone;
156	161		39. Phenampromide;
157	162		40. Phenomorphan;
158	163		41. Phenoperidine;
159	164		42. Piritramide;
160	165		43. Proheptazine;
161		-	44. Properidine;
162		-	45. Protonitazene;
163	166
164		-	ENGR. S. B. NO. 860 Page 4 1
	167	+	SENATE FLOOR VERSION - SB860 SFLR Page 4
	168	+	(Bold face denotes Committee Amendments) 1
165	169		2
166	170		3
167	171		4
168	172		5
169	173		6
170	174		7
171	175		8
172	176		9
173	177		10
174	178		11
175	179		12
176	180		13
177	181		14
178	182		15
179	183		16
180	184		17
181	185		18
182	186		19
183	187		20
184	188		21
185	189		22
186	190		23
187	191		24
188	192
	193	+	44. Properidine;
	194	+	45. Protonitazene;
189	195		46. Racemoramide; or
190	196		47. Trimeperidine.
191	197		B. Any of the following opium derivatives, their salts,
192	198		isomers, and salts of isomers, unless specifical ly excepted, when
193	199		the existence of these salts, isomers, and salts of isomers is
194	200		possible within the spe cific chemical designation:
195	201		1. Acetorphine;
196	202		2. Acetyldihydrocodeine;
197	203		3. Benzylmorphine;
198	204		4. Codeine methylbromide;
199	205		5. Codeine-N-Oxide;
200	206		6. Cyprenorphine;
201	207		7. Desomorphine;
202	208		8. Dihydromorphine;
203	209		9. Etorphine;
204	210		10. Heroin;
205	211		11. Hydromorphinol;
206	212		12. Methyldesorphine;
207	213		13. Methylhydromorphine;
208	214		14. Morphine methylbromide;
209	215		15. Morphine methylsulfonate;
210	216		16. Morphine-N-Oxide;
211		-	17. Myrophine;
212		-	18. Nicocodeine;
213	217
214		-	ENGR. S. B. NO. 860 Page 5 1
	218	+	SENATE FLOOR VERSION - SB860 SFLR Page 5
	219	+	(Bold face denotes Committee Amendments) 1
215	220		2
216	221		3
217	222		4
218	223		5
219	224		6
220	225		7
221	226		8
222	227		9
223	228		10
224	229		11
225	230		12
226	231		13
227	232		14
228	233		15
229	234		16
230	235		17
231	236		18
232	237		19
233	238		20
234	239		21
235	240		22
236	241		23
237	242		24
238	243
	244	+	17. Myrophine;
	245	+	18. Nicocodeine;
239	246		19. Nicomorphine;
240	247		20. Normorphine;
241	248		21. Phoclodine;
242	249		22. Thebacon;
243	250		23. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-acetamide
244	251		(Acetyl fentanyl);
245	252		24. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butenamide
246	253		(Crotonyl fentanyl);
247	254		25. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-2-
248	255		furancarboxamide (Furanyl fentanyl);
249	256		26. N-phenyl-1-(2-phenylethyl)-4-piperidinamine (4-ANPP);
250	257		27. N-(1-phenethylpiperidin-4-yl)-N-
251	258		phenylcyclopropanecarboxamide (Cyclopropyl fentanyl); or
252	259		28. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide
253	260		(Butyrl fentanyl).
254	261		C. Any material, compound, mixture, or preparation which
255	262		contains any quantity of the following hallucinogenic substances,
256	263		their salts, isomers, and salts of isomers, unless specifically
257	264		excepted, when the existence of these salts, isomers, and salts of
258	265		isomers is possible within the specific chemical designation:
259	266		1. Methcathinone;
260	267		2. 3, 4-methylenedioxy amphetamine;
261		-	3. 3, 4-methylenedioxy methamphetamine;
262		-	4. 5-methoxy-3, 4-methylenedioxy amphetamine;
263	268
264		-	ENGR. S. B. NO. 860 Page 6 1
	269	+	SENATE FLOOR VERSION - SB860 SFLR Page 6
	270	+	(Bold face denotes Committee Amendments) 1
265	271		2
266	272		3
267	273		4
268	274		5
269	275		6
270	276		7
271	277		8
272	278		9
273	279		10
274	280		11
275	281		12
276	282		13
277	283		14
278	284		15
279	285		16
280	286		17
281	287		18
282	288		19
283	289		20
284	290		21
285	291		22
286	292		23
287	293		24
288	294
	295	+	3. 3, 4-methylenedioxy methamphetamine;
	296	+	4. 5-methoxy-3, 4-methylenedioxy amphetamine;
289	297		5. 3, 4, 5-trimethoxy amphetamine;
290	298		6. Bufotenine;
291	299		7. Diethyltryptamine;
292	300		8. Dimethyltryptamine;
293	301		9. 4-methyl-2, 5-dimethoxyamphetamine;
294	302		10. Ibogaine;
295	303		11. Lysergic acid diethylamide;
296	304		12. Marijuana;
297	305		13. Mescaline;
298	306		14. N-benzylpiperazine;
299	307		15. N-ethyl-3-piperidyl benzilate;
300	308		16. N-methyl-3-piperidyl benzilate;
301	309		17. Psilocybin;
302	310		18. Psilocyn;
303	311		19. 2, 5 dimethoxyamphetamine;
304	312		20. 4 Bromo-2, 5-dimethoxyamphetamine;
305	313		21. 4 methoxyamphetamine;
306	314		22. Cyclohexamine;
307	315		23. Salvia Divinorum;
308	316		24. Salvinorin A;
309		-	25. Thiophene Analog of Phencyclidine. Also known as: 1 -(1-(2-
310		-	thienyl) cyclohexyl) piperidine; 2 -Thienyl Analog of Phe ncyclidine;
311		-	TPCP, TCP;
312		-	26. Phencyclidine (PCP);
313	317
314		-	ENGR. S. B. NO. 860 Page 7 1
	318	+	SENATE FLOOR VERSION - SB860 SFLR Page 7
	319	+	(Bold face denotes Committee Amendments) 1
315	320		2
316	321		3
317	322		4
318	323		5
319	324		6
320	325		7
321	326		8
322	327		9
323	328		10
324	329		11
325	330		12
326	331		13
327	332		14
328	333		15
329	334		16
330	335		17
331	336		18
332	337		19
333	338		20
334	339		21
335	340		22
336	341		23
337	342		24
338	343
	344	+	25. Thiophene Analog of Phencyclidine. Also known as: 1 -(1-(2-
	345	+	thienyl) cyclohexyl) piperidine; 2 -Thienyl Analog of Phencyclidine;
	346	+	TPCP, TCP;
	347	+	26. Phencyclidine (PCP);
339	348		27. Pyrrolidine Analog for Phencyclidine. Also known as 1 -(1-
340	349		Phenylcyclohexyl) - Pyrrolidine, PCPy, PHP;
341	350		28. 1-(3-trifluoromethylphenyl) piperazine;
342	351		29. Flunitrazepam;
343	352		30. B-hydroxy-amphetamine;
344	353		31. B-ketoamphetamine;
345	354		32. 2,5-dimethoxy-4-nitroamphetamine;
346	355		33. 2,5-dimethoxy-4-bromophenethylamine;
347	356		34. 2,5-dimethoxy-4-chlorophenethylamine;
348	357		35. 2,5-dimethoxy-4-iodoamphetamine;
349	358		36. 2,5-dimethoxy-4-iodophenethylamine;
350	359		37. 2,5-dimethoxy-4-methylphenethylamine;
351	360		38. 2,5-dimethoxy-4-ethylphenethylamine;
352	361		39. 2,5-dimethoxy-4-fluorophenethylamine;
353	362		40. 2,5-dimethoxy-4-nitrophenethylamine;
354	363		41. 2,5-dimethoxy-4-ethylthio-phenethylamine;
355	364		42. 2,5-dimethoxy-4-isopropylthio-phenethylamine;
356	365		43. 2,5-dimethoxy-4-propylthio-phenethylamine;
357	366		44. 2,5-dimethoxy-4-cyclopropylmethylthio -phenethylamine;
358	367		45. 2,5-dimethoxy-4-tert-butylthio-phenethylamine;
359		-	46. 2,5-dimethoxy-4-(2-fluoroethylthio)-phenethylamine;
360		-	47. 5-methoxy-N, N-dimethyltryptamine;
361		-	48. N-methyltryptamine;
362		-	49. A-ethyltryptamine;
363	368
364		-	ENGR. S. B. NO. 860 Page 8 1
	369	+	SENATE FLOOR VERSION - SB860 SFLR Page 8
	370	+	(Bold face denotes Committee Amendments) 1
365	371		2
366	372		3
367	373		4
368	374		5
369	375		6
370	376		7
371	377		8
372	378		9
373	379		10
374	380		11
375	381		12
376	382		13
377	383		14
378	384		15
379	385		16
380	386		17
381	387		18
382	388		19
383	389		20
384	390		21
385	391		22
386	392		23
387	393		24
388	394
	395	+	46. 2,5-dimethoxy-4-(2-fluoroethylthio)-phenethylamine;
	396	+	47. 5-methoxy-N, N-dimethyltryptamine;
	397	+	48. N-methyltryptamine;
	398	+	49. A-ethyltryptamine;
389	399		50. A-methyltryptamine;
390	400		51. N, N-diethyltryptamine;
391	401		52. N, N-diisopropyltryptamine;
392	402		53. N, N-dipropyltryptamine;
393	403		54. 5-methoxy-a-methyltryptamine;
394	404		55. 4-hydroxy-N, N-diethyltryptamine;
395	405		56. 4-hydroxy-N, N-diisopropyltryptamine;
396	406		57. 5-methoxy-N, N-diisopropyltryptamine;
397	407		58. 4-hydroxy-N-isopropyl-N-methyltryptamine;
398	408		59. 3,4-Methylenedioxymethcathinone (Methylone);
399	409		60. 3,4-Methylenedioxypyrovalerone (MDPV);
400	410		61. 3-Methylmethcathinone (Metaphedrone);
401	411		62. 4-Methylmethcathinone (Mephedrone);
402	412		63. 4-methoxymethcathinone;
403	413		64. 4-Fluoromethcathinone;
404	414		65. 3-Fluoromethcathinone;
405	415		66. 1-(8-bromobenzo 1,2-b;4,5-b’ difuran-4-yl)-2-aminopropane;
406	416		67. 2,5-Dimethoxy-4-chloroamphetamine;
407	417		68. 4-Methylethcathinone;
408	418		69. Pyrovalerone;
409		-	70. N,N-diallyl-5-methoxytryptamine;
410		-	71. 3,4-Methylenedioxy-N-ethylcathinone (Ethylone);
411		-	72. B-keto-N-Methylbenzodioxolylbutanamine (Butylone);
412		-	73. B-keto-Methylbenzodioxolylpentanamine (Pentylone);
413	419
414		-	ENGR. S. B. NO. 860 Page 9 1
	420	+	SENATE FLOOR VERSION - SB860 SFLR Page 9
	421	+	(Bold face denotes Committee Amendments) 1
415	422		2
416	423		3
417	424		4
418	425		5
419	426		6
420	427		7
421	428		8
422	429		9
423	430		10
424	431		11
425	432		12
426	433		13
427	434		14
428	435		15
429	436		16
430	437		17
431	438		18
432	439		19
433	440		20
434	441		21
435	442		22
436	443		23
437	444		24
438	445
	446	+	70. N,N-diallyl-5-methoxytryptamine;
	447	+	71. 3,4-Methylenedioxy-N-ethylcathinone (Ethylone);
	448	+	72. B-keto-N-Methylbenzodioxolylbutanamine (Butylone);
	449	+	73. B-keto-Methylbenzodioxolylpentanamine (Pentylone);
439	450		74. Alpha-Pyrrolidinopentiophenone;
440	451		75. 4-Fluoroamphetamine;
441	452		76. Pentedrone;
442	453		77. 4’-Methyl-a-pyrrolidinohexaphenone;
443	454		78. 2,5-dimethoxy-4-(n)-propylphenethylamine;
444	455		79. 2,5-dimethoxyphenethylamine;
445	456		80. 1,4-Dibenzylpiperazine;
446	457		81. N,N-Dimethylamphetamine;
447	458		82. 4-Fluoromethamphetamine;
448	459		83. 4-Chloro-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine
449	460		(25C-NBOMe);
450	461		84. 4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine
451	462		(25I-NBOMe);
452	463		85. 4-Bromo-2,5-dimethoxy-N-(2-methoxybenzy)phenethylamine
453	464		(25B-NBOMe);
454	465		86. 1-(4-Fluorophenyl)piperazine;
455	466		87. Methoxetamine;
456	467		88. 3,4-dichloro-N[2-dimethylamino)cyclohexyl] -N-
457	468		methylbenzamide;
458	469		89. N-ethyl hexadrone;
459		-	90. Isopropyl-U-47700;
460		-	91. Para-fluorobutyrl fentanyl;
461		-	92. Para-fluorofentanyl (pFF);
462		-	93. Fluoro isobutryrl fentanyl;
463	470
464		-	ENGR. S. B. NO. 860 Page 10 1
	471	+	SENATE FLOOR VERSION - SB860 SFLR Page 10
	472	+	(Bold face denotes Committee Amendments) 1
465	473		2
466	474		3
467	475		4
468	476		5
469	477		6
470	478		7
471	479		8
472	480		9
473	481		10
474	482		11
475	483		12
476	484		13
477	485		14
478	486		15
479	487		16
480	488		17
481	489		18
482	490		19
483	491		20
484	492		21
485	493		22
486	494		23
487	495		24
488	496
	497	+	90. Isopropyl-U-47700;
	498	+	91. Para-fluorobutyrl fentanyl;
	499	+	92. Para-fluorofentanyl (pFF);
	500	+	93. Fluoro isobutryrl fentanyl;
489	501		94. 3-Hydroxy Phencyclidine (PCP);
490	502		95. 3-methoxy Phencyclidine (PCP);
491	503		96. Flualprazolam; or
492	504		97. Flubromazolam.
493	505		D. Unless specifically excepted or unless listed in a different
494	506		schedule, any material, compound, mixture, or preparation which
495	507		contains any quantity of the following substances ha ving stimulant
496	508		or depressant effect on the central nervous system:
497	509		1. Fenethylline;
498	510		2. Mecloqualone;
499	511		3. N-ethylamphetamine;
500	512		4. Methaqualone;
501	513		5. Gamma-Hydroxybutyric Acid, also known as GHB, gamma -
502	514		hydroxybutyrate, 4-hydroxybutyrate, 4-hydroxybutanoic acid, sodium
503	515		oxybate, and sodium oxybutyrate;
504	516		6. Gamma-Butyrolactone (GBL) as packaged, marketed,
505	517		manufactured, or promoted for human consumption, with the exception
506	518		of legitimate food additive and manufacturing purposes;
507		-	7. Gamma Hydroxyvalerate (GHV) as packag ed, marketed, or
508		-	manufactured for human consumption, with the exception of legitimate
509		-	food additive and manufacturing purposes;
510		-	8. Gamma Valerolactone (GVL) as packaged, marketed, or
511		-	manufactured for human consumption, with the exception of legitimate
512		-	food additive and manufacturing purposes;
513	519
514		-	ENGR. S. B. NO. 860 Page 11 1
	520	+	SENATE FLOOR VERSION - SB860 SFLR Page 11
	521	+	(Bold face denotes Committee Amendments) 1
515	522		2
516	523		3
517	524		4
518	525		5
519	526		6
520	527		7
521	528		8
522	529		9
523	530		10
524	531		11
525	532		12
526	533		13
527	534		14
528	535		15
529	536		16
530	537		17
531	538		18
532	539		19
533	540		20
534	541		21
535	542		22
536	543		23
537	544		24
538	545
	546	+	7. Gamma Hydroxyvalerate (GHV) as packaged, marketed, or
	547	+	manufactured for human consumption, with the exception of legitimate
	548	+	food additive and manufacturing purposes;
	549	+	8. Gamma Valerolactone (GVL) as packaged, marketed, or
	550	+	manufactured for human consumption, with the exception of legitim ate
	551	+	food additive and manufacturing purposes;
539	552		9. 1,4 Butanediol (1,4 BD or BDO) as packaged, marketed,
540	553		manufactured, or promoted for human consumption with the exception
541	554		of legitimate manufacturing purposes; or
542	555		10. N-ethylpentylone.
543	556		E. 1. The following industrial uses of Gamma -Butyrolactone,
544	557		Gamma Hydroxyvalerate, Gamma Valerolactone, or 1,4 Butanediol are
545	558		excluded from all schedules of controlled substances under this
546	559		title:
547	560		a. pesticides,
548	561		b. photochemical etching,
549	562		c. electrolytes of small batteries or capacitors,
550	563		d. viscosity modifiers in polyurethane,
551	564		e. surface etching of metal coated plastics,
552	565		f. organic paint disbursements for water soluble inks,
553	566		g. pH regulators in the dyeing of wool and polyamide
554	567		fibers,
555	568		h. foundry chemistry as a catalyst during curing,
556		-	i. curing agents in many coating systems based on
557		-	urethanes and amides,
558		-	j. additives and flavoring agents in food, confectionary,
559		-	and beverage products,
560		-	k. synthetic fiber and clothing production,
561		-	l. tetrahydrofuran production,
562		-	m. gamma butyrolactone prod uction,
563	569
564		-	ENGR. S. B. NO. 860 Page 12 1
	570	+	SENATE FLOOR VERSION - SB860 SFLR Page 12
	571	+	(Bold face denotes Committee Amendments) 1
565	572		2
566	573		3
567	574		4
568	575		5
569	576		6
570	577		7
571	578		8
572	579		9
573	580		10
574	581		11
575	582		12
576	583		13
577	584		14
578	585		15
579	586		16
580	587		17
581	588		18
582	589		19
583	590		20
584	591		21
585	592		22
586	593		23
587	594		24
588	595
	596	+	i. curing agents in many coating systems based on
	597	+	urethanes and amides,
	598	+	j. additives and flavoring agents in food, confectionary,
	599	+	and beverage products,
	600	+	k. synthetic fiber and clothing production,
	601	+	l. tetrahydrofuran production,
	602	+	m. gamma butyrolactone production,
589	603		n. polybutylene terephthalate resin production,
590	604		o. polyester raw materials for polyurethane elastomers
591	605		and foams,
592	606		p. coating resin raw ma terial, and
593	607		q. as an intermediate in the manufacture of other
594	608		chemicals and pharmaceuticals.
595	609		2. At the request of any person, the Director of the Oklahoma
596	610		State Bureau of Narcotics and Dangerous Drugs Control may exempt any
597	611		other product containing Gamma -Butyrolactone, Gamma Hydroxyvalerate,
598	612		Gamma Valerolactone, or 1,4 Butanediol from being included as a
599	613		Schedule I controlled substance if such product is labeled,
600	614		marketed, manufactured , and distributed for legitimate industrial
601	615		use in a manner that reduces or eliminates the likelihood of abuse.
602	616		3. In making a determination regarding an industrial product,
603	617		the Director, after notice and hearing, shall consider the
604	618		following:
605	619		a. the history and current pattern of abuse,
606		-	b. the name and labeling of the product,
607		-	c. the intended manner of distribution, advertising , and
608		-	promotion of the product, and
609		-	d. other factors as may be relevant to and consistent
610		-	with the public health and safety.
611		-	4. The hearing shall be held in accordance with the procedures
612		-	of the Administrative Procedures Act.
613	620
614		-	ENGR. S. B. NO. 860 Page 13 1
	621	+	SENATE FLOOR VERSION - SB860 SFLR Page 13
	622	+	(Bold face denotes Committee Amendments) 1
615	623		2
616	624		3
617	625		4
618	626		5
619	627		6
620	628		7
621	629		8
622	630		9
623	631		10
624	632		11
625	633		12
626	634		13
627	635		14
628	636		15
629	637		16
630	638		17
631	639		18
632	640		19
633	641		20
634	642		21
635	643		22
636	644		23
637	645		24
638	646
	647	+	b. the name and labeling of the product,
	648	+	c. the intended manner of distribution, advertising , and
	649	+	promotion of the product, and
	650	+	d. other factors as may be relevant to and consistent
	651	+	with the public health and safety.
	652	+	4. The hearing shall be held in accordance with the procedures
	653	+	of the Administrative Procedures Act.
639	654		F. Any material, compound, mixture, or preparation, whether
640	655		produced directly or indirectly from a substance of vegetable origin
641	656		or independently by means of chemical synthesis, or by a combination
642	657		of extraction and chemical synthesis, that contains any quantity of
643	658		the following substances, or that contains any of their salts,
644	659		isomers, and salts of isomers when the existence of these salts,
645	660		isomers, and salts of isomers is possible within the specific
646	661		chemical designation:
647	662		1. JWH-004;
648	663		2. JWH-007;
649	664		3. JWH-009;
650	665		4. JWH-015;
651	666		5. JWH-016;
652	667		6. JWH-018;
653	668		7. JWH-019;
654	669		8. JWH-020;
655	670		9. JWH-030;
656		-	10. JWH-046;
657		-	11. JWH-047;
658		-	12. JWH-048;
659		-	13. JWH-049;
660		-	14. JWH-050;
661		-	15. JWH-070;
662		-	16. JWH-071;
663	671
664		-	ENGR. S. B. NO. 860 Page 14 1
	672	+	SENATE FLOOR VERSION - SB860 SFLR Page 14
	673	+	(Bold face denotes Committee Amendments) 1
665	674		2
666	675		3
667	676		4
668	677		5
669	678		6
670	679		7
671	680		8
672	681		9
673	682		10
674	683		11
675	684		12
676	685		13
677	686		14
678	687		15
679	688		16
680	689		17
681	690		18
682	691		19
683	692		20
684	693		21
685	694		22
686	695		23
687	696		24
688	697
	698	+	10. JWH-046;
	699	+	11. JWH-047;
	700	+	12. JWH-048;
	701	+	13. JWH-049;
	702	+	14. JWH-050;
	703	+	15. JWH-070;
	704	+	16. JWH-071;
689	705		17. JWH-072;
690	706		18. JWH-073;
691	707		19. JWH-076;
692	708		20. JWH-079;
693	709		21. JWH-080;
694	710		22. JWH-081;
695	711		23. JWH-082;
696	712		24. JWH-094;
697	713		25. JWH-096;
698	714		26. JWH-098;
699	715		27. JWH-116;
700	716		28. JWH-120;
701	717		29. JWH-122;
702	718		30. JWH-145;
703	719		31. JWH-146;
704	720		32. JWH-147;
705	721		33. JWH-148;
706		-	34. JWH-149;
707		-	35. JWH-150;
708		-	36. JWH-156;
709		-	37. JWH-167;
710		-	38. JWH-175;
711		-	39. JWH-180;
712		-	40. JWH-181;
713	722
714		-	ENGR. S. B. NO. 860 Page 15 1
	723	+	SENATE FLOOR VERSION - SB860 SFLR Page 15
	724	+	(Bold face denotes Committee Amendments) 1
715	725		2
716	726		3
717	727		4
718	728		5
719	729		6
720	730		7
721	731		8
722	732		9
723	733		10
724	734		11
725	735		12
726	736		13
727	737		14
728	738		15
729	739		16
730	740		17
731	741		18
732	742		19
733	743		20
734	744		21
735	745		22
736	746		23
737	747		24
738	748
	749	+	34. JWH-149;
	750	+	35. JWH-150;
	751	+	36. JWH-156;
	752	+	37. JWH-167;
	753	+	38. JWH-175;
	754	+	39. JWH-180;
	755	+	40. JWH-181;
739	756		41. JWH-182;
740	757		42. JWH-184;
741	758		43. JWH-185;
742	759		44. JWH-189;
743	760		45. JWH-192;
744	761		46. JWH-193;
745	762		47. JWH-194;
746	763		48. JWH-195;
747	764		49. JWH-196;
748	765		50. JWH-197;
749	766		51. JWH-198;
750	767		52. JWH-199;
751	768		53. JWH-200;
752	769		54. JWH-201;
753	770		55. JWH-202;
754	771		56. JWH-203;
755	772		57. JWH-204;
756		-	58. JWH-205;
757		-	59. JWH-206;
758		-	60. JWH-207;
759		-	61. JWH-208;
760		-	62. JWH-209;
761		-	63. JWH-210;
762		-	64. JWH-211;
763	773
764		-	ENGR. S. B. NO. 860 Page 16 1
	774	+	SENATE FLOOR VERSION - SB860 SFLR Page 16
	775	+	(Bold face denotes Committee Amendments) 1
765	776		2
766	777		3
767	778		4
768	779		5
769	780		6
770	781		7
771	782		8
772	783		9
773	784		10
774	785		11
775	786		12
776	787		13
777	788		14
778	789		15
779	790		16
780	791		17
781	792		18
782	793		19
783	794		20
784	795		21
785	796		22
786	797		23
787	798		24
788	799
	800	+	58. JWH-205;
	801	+	59. JWH-206;
	802	+	60. JWH-207;
	803	+	61. JWH-208;
	804	+	62. JWH-209;
	805	+	63. JWH-210;
	806	+	64. JWH-211;
789	807		65. JWH-212;
790	808		66. JWH-213;
791	809		67. JWH-234;
792	810		68. JWH-235;
793	811		69. JWH-236;
794	812		70. JWH-237;
795	813		71. JWH-239;
796	814		72. JWH-240;
797	815		73. JWH-241;
798	816		74. JWH-242;
799	817		75. JWH-243;
800	818		76. JWH-244;
801	819		77. JWH-245;
802	820		78. JWH-246;
803	821		79. JWH-248;
804	822		80. JWH-249;
805	823		81. JWH-250;
806		-	82. JWH-251;
807		-	83. JWH-252;
808		-	84. JWH-253;
809		-	85. JWH-262;
810		-	86. JWH-292;
811		-	87. JWH-293;
812		-	88. JWH-302;
813	824
814		-	ENGR. S. B. NO. 860 Page 17 1
	825	+	SENATE FLOOR VERSION - SB860 SFLR Page 17
	826	+	(Bold face denotes Committee Amendments) 1
815	827		2
816	828		3
817	829		4
818	830		5
819	831		6
820	832		7
821	833		8
822	834		9
823	835		10
824	836		11
825	837		12
826	838		13
827	839		14
828	840		15
829	841		16
830	842		17
831	843		18
832	844		19
833	845		20
834	846		21
835	847		22
836	848		23
837	849		24
838	850
	851	+	82. JWH-251;
	852	+	83. JWH-252;
	853	+	84. JWH-253;
	854	+	85. JWH-262;
	855	+	86. JWH-292;
	856	+	87. JWH-293;
	857	+	88. JWH-302;
839	858		89. JWH-303;
840	859		90. JWH-304;
841	860		91. JWH-305;
842	861		92. JWH-306;
843	862		93. JWH-307;
844	863		94. JWH-308;
845	864		95. JWH-311;
846	865		96. JWH-312;
847	866		97. JWH-313;
848	867		98. JWH-314;
849	868		99. JWH-315;
850	869		100. JWH-316;
851	870		101. JWH-346;
852	871		102. JWH-348;
853	872		103. JWH-363;
854	873		104. JWH-364;
855	874		105. JWH-365;
856		-	106. JWH-367;
857		-	107. JWH-368;
858		-	108. JWH-369;
859		-	109. JWH-370;
860		-	110. JWH-371;
861		-	111. JWH-373;
862		-	112. JWH-386;
863	875
864		-	ENGR. S. B. NO. 860 Page 18 1
	876	+	SENATE FLOOR VERSION - SB860 SFLR Page 18
	877	+	(Bold face denotes Committee Amendments) 1
865	878		2
866	879		3
867	880		4
868	881		5
869	882		6
870	883		7
871	884		8
872	885		9
873	886		10
874	887		11
875	888		12
876	889		13
877	890		14
878	891		15
879	892		16
880	893		17
881	894		18
882	895		19
883	896		20
884	897		21
885	898		22
886	899		23
887	900		24
888	901
	902	+	106. JWH-367;
	903	+	107. JWH-368;
	904	+	108. JWH-369;
	905	+	109. JWH-370;
	906	+	110. JWH-371;
	907	+	111. JWH-373;
	908	+	112. JWH-386;
889	909		113. JWH-387;
890	910		114. JWH-392;
891	911		115. JWH-394;
892	912		116. JWH-395;
893	913		117. JWH-397;
894	914		118. JWH-398;
895	915		119. JWH-399;
896	916		120. JWH-400;
897	917		121. JWH-412;
898	918		122. JWH-413;
899	919		123. JWH-414;
900	920		124. JWH-415;
901	921		125. CP-55, 940;
902	922		126. CP-47, 497;
903	923		127. HU-210;
904	924		128. HU-211;
905	925		129. WIN-55, 212-2;
906		-	130. AM-2201;
907		-	131. AM-2233;
908		-	132. JWH-018 adamantyl-carboxamide;
909		-	133. AKB48;
910		-	134. JWH-122 N-(4-pentenyl)analog;
911		-	135. MAM2201;
912		-	136. URB597;
913	926
914		-	ENGR. S. B. NO. 860 Page 19 1
	927	+	SENATE FLOOR VERSION - SB860 SFLR Page 19
	928	+	(Bold face denotes Committee Amendments) 1
915	929		2
916	930		3
917	931		4
918	932		5
919	933		6
920	934		7
921	935		8
922	936		9
923	937		10
924	938		11
925	939		12
926	940		13
927	941		14
928	942		15
929	943		16
930	944		17
931	945		18
932	946		19
933	947		20
934	948		21
935	949		22
936	950		23
937	951		24
938	952
	953	+	130. AM-2201;
	954	+	131. AM-2233;
	955	+	132. JWH-018 adamantyl-carboxamide;
	956	+	133. AKB48;
	957	+	134. JWH-122 N-(4-pentenyl)analog;
	958	+	135. MAM2201;
	959	+	136. URB597;
939	960		137. URB602;
940	961		138. URB754;
941	962		139. UR144;
942	963		140. XLR11;
943	964		141. A-796,260;
944	965		142. STS-135;
945	966		143. AB-FUBINACA;
946	967		144. AB-PINACA;
947	968		145. PB-22;
948	969		146. AKB48 N-5-Fluorpentyl;
949	970		147. AM1248;
950	971		148. FUB-PB-22;
951	972		149. ADB-FUBINACA;
952	973		150. BB-22;
953	974		151. 5-Fluoro PB-22; or
954	975		152. 5-Fluoro AKB-48.
955		-	G. In addition to those substances listed in subsection F of
956		-	this section, unless specifically excepted or unless listed in
957		-	another schedule, any material, compound , mixture, or preparation
958		-	which contains any quantity of a synthetic cannabinoid found to be
959		-	in any of the following chemical groups:
960		-	1. Naphthoylindoles: any compound containing a 3 -(1-
961		-	naphthoyl)indole structure with or without substitution at the
962		-	nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
963	976
964		-	ENGR. S. B. NO. 860 Page 20 1
	977	+	SENATE FLOOR VERSION - SB860 SFLR Page 20
	978	+	(Bold face denotes Committee Amendments) 1
965	979		2
966	980		3
967	981		4
968	982		5
969	983		6
970	984		7
971	985		8
972	986		9
973	987		10
974	988		11
975	989		12
976	990		13
977	991		14
978	992		15
979	993		16
980	994		17
981	995		18
982	996		19
983	997		20
984	998		21
985	999		22
986	1000		23
987	1001		24
988	1002
	1003	+	G. In addition to those substances listed in subsection F of
	1004	+	this section, unless specifically excepted or unless listed in
	1005	+	another schedule, any material, c ompound, mixture, or preparation
	1006	+	which contains any quantity of a synthetic cannabinoid found to be
	1007	+	in any of the following chemical groups:
	1008	+	1. Naphthoylindoles: any compound containing a 3 -(1-
	1009	+	naphthoyl)indole structure with or without substitution at th e
	1010	+	nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
989	1011		alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -
990	1012		(N-methyl-2-piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1 -(N-methyl-
991	1013		2-pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl,
992	1014		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
993	1015		halophenyl group, whether or not further substituted on the indole
994	1016		ring to any extent, and whether or not substituted on the naphthyl
995	1017		ring to any extent. Naphthoylindoles include, but are n ot limited
996	1018		to:
997	1019		a. 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH -
998	1020		200),
999	1021		b. 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201),
1000	1022		c. 1-pentyl-3-(1-naphthoyl)indole (JWH -018),
1001	1023		d. 1-butyl-3-(1-naphthoyl)indole (JWH -073),
1002	1024		e. 1-pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081),
1003	1025		f. 1-propyl-2-methyl-3-(1-naphthoyl)indole (JWH -015),
1004	1026		g. 1-hexyl-3-(1-naphthoyl)indole (JWH -019),
1005		-	h. 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122),
1006		-	i. 1-pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH -210),
1007		-	j. 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398),
1008		-	k. 1-pentyl-2-methyl-3-(1-naphthoyl)indole (JWH -007),
1009		-	l. 1-pentyl-3-(7-methoxy-1-naphthoyl)indole (JWH -164),
1010		-	m. 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole
1011		-	(JWH-098),
1012		-	n. 1-pentyl-3-(4-fluoro-1-naphthoyl)indole (JWH -412),
1013	1027
1014		-	ENGR. S. B. NO. 860 Page 21 1
	1028	+	SENATE FLOOR VERSION - SB860 SFLR Page 21
	1029	+	(Bold face denotes Committee Amendments) 1
1015	1030		2
1016	1031		3
1017	1032		4
1018	1033		5
1019	1034		6
1020	1035		7
1021	1036		8
1022	1037		9
1023	1038		10
1024	1039		11
1025	1040		12
1026	1041		13
1027	1042		14
1028	1043		15
1029	1044		16
1030	1045		17
1031	1046		18
1032	1047		19
1033	1048		20
1034	1049		21
1035	1050		22
1036	1051		23
1037	1052		24
1038	1053
	1054	+	h. 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122),
	1055	+	i. 1-pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH -210),
	1056	+	j. 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398),
	1057	+	k. 1-pentyl-2-methyl-3-(1-naphthoyl)indole (JWH -007),
	1058	+	l. 1-pentyl-3-(7-methoxy-1-naphthoyl)indole (JWH -164),
	1059	+	m. 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole
	1060	+	(JWH-098),
	1061	+	n. 1-pentyl-3-(4-fluoro-1-naphthoyl)indole (JWH -412),
1039	1062		o. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(1-
1040	1063		naphthoyl)indole (AM -1220),
1041	1064		p. 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole
1042	1065		(MAM-2201), or
1043	1066		q. 1-(4-cyanobutyl)-3-(1-naphthoyl)indole (AM -2232);
1044	1067		2. Naphthylmethylindoles: any compound containing a 1H -indol-
1045	1068		3-yl-(1-naphthyl)methane structure with or without substitution at
1046	1069		the nitrogen atom of the indole ring by an alkyl, haloalkyl,
1047	1070		cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
1048	1071		halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2 -(4-
1049	1072		morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3-
1050	1073		morpholinyl)methyl, (tetrahydropyran -4-yl)methyl, 1-methylazepanyl,
1051	1074		phenyl, or halophenyl group, whet her or not further substituted on
1052	1075		the indole ring to any extent, and whether or not substituted on the
1053	1076		naphthyl ring to any extent. Naphthylmethylindoles include, but are
1054	1077		not limited to, (1-pentylindol-3-yl)(1-naphthyl)methane (JWH -175);
1055		-	3. Naphthoylpyrroles: any compound containing a 3 -(1-
1056		-	naphthoyl)pyrrole structure with or without substitution at the
1057		-	nitrogen atom of the pyrrole ring by an alkyl, haloalkyl,
1058		-	cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
1059		-	halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
1060		-	morpholinyl)ethyl, 1 -(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3-
1061		-	morpholinyl)methyl, (tet rahydropyran-4-yl)methyl, 1-methylazepanyl,
1062		-	phenyl, or halophenyl group, whether or not further substituted on
1063	1078
1064		-	ENGR. S. B. NO. 860 Page 22 1
	1079	+	SENATE FLOOR VERSION - SB860 SFLR Page 22
	1080	+	(Bold face denotes Committee Amendments) 1
1065	1081		2
1066	1082		3
1067	1083		4
1068	1084		5
1069	1085		6
1070	1086		7
1071	1087		8
1072	1088		9
1073	1089		10
1074	1090		11
1075	1091		12
1076	1092		13
1077	1093		14
1078	1094		15
1079	1095		16
1080	1096		17
1081	1097		18
1082	1098		19
1083	1099		20
1084	1100		21
1085	1101		22
1086	1102		23
1087	1103		24
1088	1104
	1105	+	3. Naphthoylpyrroles: any compound containing a 3 -(1-
	1106	+	naphthoyl)pyrrole structure with or without substitution at the
	1107	+	nitrogen atom of the pyrrole ring by an alkyl, haloalkyl,
	1108	+	cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
	1109	+	halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
	1110	+	morpholinyl)ethyl, 1 -(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3-
	1111	+	morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
	1112	+	phenyl, or halophenyl group, whether or not further substituted on
1089	1113		the pyrrole ring to any extent, and whether or not substituted on
1090	1114		the naphthyl group to any extent. Naphthoylpyrroles include, but
1091	1115		are not limited to:
1092	1116		a. 1-hexyl-2-phenyl-4-(1-naphthoyl)pyrrole (JWH -147),
1093	1117		b. 1-pentyl-5-(2-methylphenyl)-3-(1-naphthoyl)pyrrole
1094	1118		(JWH-370),
1095	1119		c. 1-pentyl-3-(1-naphthoyl)pyrrole (JWH -030), or
1096	1120		d. 1-hexyl-5-phenyl-3-(1-naphthoyl)pyrrole (JWH -147);
1097	1121		4. Naphthylideneind enes: any compound containing a 1 -(1-
1098	1122		naphthylmethylene)indene structure with or without substitution at
1099	1123		the 3-position of the indene ring by an alkyl, haloalkyl,
1100	1124		cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
1101	1125		halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
1102	1126		morpholinyl)ethyl, 1 -(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3-
1103	1127		morpholinyl)methyl, (tetrahydropyran -4-yl)methyl, 1-methylazepanyl,
1104	1128		phenyl, or halophenyl group, whether or not further substituted on
1105		-	the indene group to any extent, and wh ether or not substituted on
1106		-	the naphthyl group to any extent. Naphthylmethylindenes include,
1107		-	but are not limited to, (1 -[(3-pentyl)-1H-inden-1-
1108		-	ylidene)methyl]naphthalene (JWH -176);
1109		-	5. Phenylacetylindoles: any compound containing a 3 -
1110		-	phenylacetylindole s tructure with or without substitution at the
1111		-	nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl,
1112		-	alkenyl, cycloalkylmethyl, cycloal kylethyl, benzyl, halobenzyl, 1 -
1113	1129
1114		-	ENGR. S. B. NO. 860 Page 23 1
	1130	+	SENATE FLOOR VERSION - SB860 SFLR Page 23
	1131	+	(Bold face denotes Committee Amendments) 1
1115	1132		2
1116	1133		3
1117	1134		4
1118	1135		5
1119	1136		6
1120	1137		7
1121	1138		8
1122	1139		9
1123	1140		10
1124	1141		11
1125	1142		12
1126	1143		13
1127	1144		14
1128	1145		15
1129	1146		16
1130	1147		17
1131	1148		18
1132	1149		19
1133	1150		20
1134	1151		21
1135	1152		22
1136	1153		23
1137	1154		24
1138	1155
	1156	+	the indene group to any extent, and whether or not substituted on
	1157	+	the naphthyl group to any extent. Naphthylmethylindenes include,
	1158	+	but are not limited to, (1 -[(3-pentyl)-1H-inden-1-
	1159	+	ylidene)methyl]naphthalene (JWH -176);
	1160	+	5. Phenylacetylindoles: any compound containing a 3 -
	1161	+	phenylacetylindole structure with or without substitution at the
	1162	+	nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl,
	1163	+	alkenyl, cycloalkylmethyl, cycloal kylethyl, benzyl, halobenzyl, 1 -
1139	1164		(N-methyl-2-piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1 -(N-methyl-
1140	1165		2-pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl,
1141	1166		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
1142	1167		halophenyl group, whether or not further substituted on the indole
1143	1168		ring to any extent, and whether or not substituted on the phenyl
1144	1169		ring to any extent. Phenylacetylindoles include, but are not
1145	1170		limited to:
1146	1171		a. 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH -250),
1147	1172		b. 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole
1148	1173		(RCS-8),
1149	1174		c. 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH -203),
1150	1175		d. 1-pentyl-3-(2-methylphenylacetyl)indole (JWH -251),
1151	1176		e. 1-pentyl-3-(4-methoxyphenylacetyl)indole (JWH -201), or
1152	1177		f. 1-pentyl-3-(3-methoxyphenylacetyl)indole (JWH -302);
1153	1178		6. Cyclohexylphenols: any compound containing a 2 -(3-
1154	1179		hydroxycyclohexyl)phenol structure with or without s ubstitution at
1155		-	the 5-position of the phenolic ring by an alkyl, haloalkyl,
1156		-	cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
1157		-	halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2 -(4-
1158		-	morpholinyl)ethyl, 1 -(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3-
1159		-	morpholinyl)methyl, (tetrahydropyran -4-yl)methyl, 1-methylazepanyl,
1160		-	phenyl, or halophenyl group, and whether or not further substituted
1161		-	on the cyclohexyl ring to any extent. Cyclohexylphenols include,
1162		-	but are not limited to:
1163	1180
1164		-	ENGR. S. B. NO. 860 Page 24 1
	1181	+	SENATE FLOOR VERSION - SB860 SFLR Page 24
	1182	+	(Bold face denotes Committee Amendments) 1
1165	1183		2
1166	1184		3
1167	1185		4
1168	1186		5
1169	1187		6
1170	1188		7
1171	1189		8
1172	1190		9
1173	1191		10
1174	1192		11
1175	1193		12
1176	1194		13
1177	1195		14
1178	1196		15
1179	1197		16
1180	1198		17
1181	1199		18
1182	1200		19
1183	1201		20
1184	1202		21
1185	1203		22
1186	1204		23
1187	1205		24
1188	1206
	1207	+	the 5-position of the phenolic ring by an alkyl, haloalkyl,
	1208	+	cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
	1209	+	halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2 -(4-
	1210	+	morpholinyl)ethyl, 1 -(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3-
	1211	+	morpholinyl)methyl, (tetrahydropyran -4-yl)methyl, 1-methylazepanyl,
	1212	+	phenyl, or halophenyl group, and whether or not further substituted
	1213	+	on the cyclohexyl ring to any extent. Cyclohexylphenols include,
	1214	+	but are not limited to:
1189	1215		a. 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-
1190	1216		hydroxycyclohexyl]-phenol (CP-47,497),
1191	1217		b. 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-
1192	1218		phenol (cannabicyclohexanol; CP -47,497 C8 homologue),
1193	1219		or
1194	1220		c. 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-
1195	1221		hydroxypropyl)cyclohexyl] -phenol (CP 55, 940);
1196	1222		7. Benzoylindoles: any compound containing a 3 -(benzoyl)indole
1197	1223		structure with or without substitution at the nitrogen atom of the
1198	1224		indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
1199	1225		cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -(N-methyl-
1200	1226		2-piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1 -(N-methyl-2-
1201	1227		pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl,
1202	1228		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
1203	1229		halophenyl group, whether or not further substituted on the indole
1204	1230		ring to any extent, and whether or not substituted on the phenyl
1205		-	group to any extent. Benzoylindoles include, but are not limited
1206		-	to:
1207		-	a. 1-pentyl-3-(4-methoxybenzoyl)indole (RCS -4),
1208		-	b. 1-[2-(4-morpholinyl)ethyl]-2-methyl-3-(4-
1209		-	methoxybenzoyl)indole (Pravadoline or WIN 48, 098),
1210		-	c. 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM -694),
1211		-	d. 1-pentyl-3-(2-iodobenzoyl)indole (AM -679), or
1212	1231
1213		-	ENGR. S. B. NO. 860 Page 25 1
	1232	+	SENATE FLOOR VERSION - SB860 SFLR Page 25
	1233	+	(Bold face denotes Committee Amendments) 1
1214	1234		2
1215	1235		3
1216	1236		4
1217	1237		5
1218	1238		6
1219	1239		7
1220	1240		8
1221	1241		9
1222	1242		10
1223	1243		11
1224	1244		12
1225	1245		13
1226	1246		14
1227	1247		15
1228	1248		16
1229	1249		17
1230	1250		18
1231	1251		19
1232	1252		20
1233	1253		21
1234	1254		22
1235	1255		23
1236	1256		24
1237	1257
	1258	+	group to any extent. Benzoylindoles include, but are not limited
	1259	+	to:
	1260	+	a. 1-pentyl-3-(4-methoxybenzoyl)indole (RCS -4),
	1261	+	b. 1-[2-(4-morpholinyl)ethyl]-2-methyl-3-(4-
	1262	+	methoxybenzoyl)indole (Pravadoline or WIN 48, 098),
	1263	+	c. 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM -694),
	1264	+	d. 1-pentyl-3-(2-iodobenzoyl)indole (AM -679), or
1238	1265		e. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(2-
1239	1266		iodobenzoyl)indole (AM -2233);
1240	1267		8. Cyclopropoylindoles: Any compound containing a 3 -
1241	1268		(cyclopropoyl)indole structure with substitution at the nitrogen
1242	1269		atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
1243	1270		cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -(N-methyl-
1244	1271		2-piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1 -(N-methyl-2-
1245	1272		pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl,
1246	1273		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
1247	1274		halophenyl group, whether or not furt her substituted in the indole
1248	1275		ring to any extent, and whether or not substituted in the
1249	1276		cyclopropoyl ring to any extent. Cyclopropoylindoles include, but
1250	1277		are not limited to:
1251	1278		a. 1-pentyl-3-(2,2,3,3-tetramethylcyclopropoyl)indole
1252	1279		(UR-144),
1253	1280		b. 1-(5-chloropentyl)-3-(2,2,3,3-
1254	1281		tetramethylcyclopropoyl)indole (5Cl -UR-144), or
1255		-	c. 1-(5-fluoropentyl)-3-(2,2,3,3-
1256		-	tetramethylcyclopropoyl)indole (XLR11);
1257		-	9. Indole Amides: Any compound containing a 1H -Indole-3-
1258		-	carboxamide structure with or without substitution at the nit rogen
1259		-	atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
1260		-	cycloalkylmethyl, cycloalkylethyl, b enzyl, halobenzyl, 1 -(N-methyl-
1261		-	2-piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1 -(N-methyl-2-
1262	1282
1263		-	ENGR. S. B. NO. 860 Page 26 1
	1283	+	SENATE FLOOR VERSION - SB860 SFLR Page 26
	1284	+	(Bold face denotes Committee Amendments) 1
1264	1285		2
1265	1286		3
1266	1287		4
1267	1288		5
1268	1289		6
1269	1290		7
1270	1291		8
1271	1292		9
1272	1293		10
1273	1294		11
1274	1295		12
1275	1296		13
1276	1297		14
1277	1298		15
1278	1299		16
1279	1300		17
1280	1301		18
1281	1302		19
1282	1303		20
1283	1304		21
1284	1305		22
1285	1306		23
1286	1307		24
1287	1308
	1309	+	c. 1-(5-fluoropentyl)-3-(2,2,3,3-
	1310	+	tetramethylcyclopropoyl)indole (XLR11);
	1311	+	9. Indole Amides: Any compound containing a 1H -Indole-3-
	1312	+	carboxamide structure with or without substitution at the nit rogen
	1313	+	atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
	1314	+	cycloalkylmethyl, cycloalkyle thyl, benzyl, halobenzyl, 1 -(N-methyl-
	1315	+	2-piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1 -(N-methyl-2-
1288	1316		pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl,
1289	1317		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
1290	1318		halophenyl group, whether or not substitute d at the carboxamide
1291	1319		group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
1292	1320		cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
1293	1321		1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
1294	1322		dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
1295	1323		further substituted in the indole, adamantyl, naphthyl, phenyl,
1296	1324		pyrrole, quninolinyl, or cycloalkyl rings to any extent. Indole
1297	1325		Amides include, but are not limited to:
1298	1326		a. N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide
1299	1327		(2NE1),
1300	1328		b. N-(1-adamantyl)-1-(5-fluoropentyl-1H-indole-3-
1301	1329		carboxamide (STS-135),
1302	1330		c. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
1303	1331		indole-3-carboxamide (ADBICA) ,
1304		-	d. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-
1305		-	fluoropentyl)-1H-indole-3-carboxamide (5F-ADBICA),
1306		-	e. N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide
1307		-	(NNE1),
1308		-	f. 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3-
1309		-	carboxamide (5F-NNE1),
1310		-	g. N-benzyl-1-pentyl-1H-indole-3-carboxamide (SDB-006),
1311		-	or
1312	1332
1313		-	ENGR. S. B. NO. 860 Page 27 1
	1333	+	SENATE FLOOR VERSION - SB860 SFLR Page 27
	1334	+	(Bold face denotes Committee Amendments) 1
1314	1335		2
1315	1336		3
1316	1337		4
1317	1338		5
1318	1339		6
1319	1340		7
1320	1341		8
1321	1342		9
1322	1343		10
1323	1344		11
1324	1345		12
1325	1346		13
1326	1347		14
1327	1348		15
1328	1349		16
1329	1350		17
1330	1351		18
1331	1352		19
1332	1353		20
1333	1354		21
1334	1355		22
1335	1356		23
1336	1357		24
1337	1358
	1359	+	d. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-
	1360	+	fluoropentyl)-1H-indole-3-carboxamide (5F-ADBICA),
	1361	+	e. N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide
	1362	+	(NNE1),
	1363	+	f. 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3-
	1364	+	carboxamide (5F-NNE1),
	1365	+	g. N-benzyl-1-pentyl-1H-indole-3-carboxamide (SDB-006),
	1366	+	or
1338	1367		h. N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide
1339	1368		(5F-SDB-006);
1340	1369		10. Indole Esters: Any compound containing a 1H -Indole-3-
1341	1370		carboxylate structure with or without substitution at the nitrogen
1342	1371		atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
1343	1372		cycloalkylmethyl, cycloalkylethyl, benzyl, halobe nzyl, 1-(N-methyl-
1344	1373		2-piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1 -(N-methyl-2-
1345	1374		pyrrolidinyl)methyl, 1 -(N-methyl-3-morpholinyl)methyl,
1346	1375		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
1347	1376		halophenyl group, whether or not substituted at the carboxylate
1348	1377		group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
1349	1378		cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
1350	1379		1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
1351	1380		dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
1352	1381		further substituted in the indole, adamantyl, naphthyl, phenyl,
1353		-	pyrrole, quinolinyl, or cycloalkyl rings to any extent. Indole
1354		-	Esters include, but are not limited to:
1355		-	a. quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-
1356		-	22),
1357		-	b. quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-
1358		-	carboxylate (5F-PB-22),
1359		-	c. quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-
1360		-	carboxylate (BB-22),
1361	1382
1362		-	ENGR. S. B. NO. 860 Page 28 1
	1383	+	SENATE FLOOR VERSION - SB860 SFLR Page 28
	1384	+	(Bold face denotes Committee Amendments) 1
1363	1385		2
1364	1386		3
1365	1387		4
1366	1388		5
1367	1389		6
1368	1390		7
1369	1391		8
1370	1392		9
1371	1393		10
1372	1394		11
1373	1395		12
1374	1396		13
1375	1397		14
1376	1398		15
1377	1399		16
1378	1400		17
1379	1401		18
1380	1402		19
1381	1403		20
1382	1404		21
1383	1405		22
1384	1406		23
1385	1407		24
1386	1408
	1409	+	pyrrole, quinolinyl, or cycloalkyl rings to any extent. Indole
	1410	+	Esters include, but are not limited to:
	1411	+	a. quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-
	1412	+	22),
	1413	+	b. quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-
	1414	+	carboxylate (5F-PB-22),
	1415	+	c. quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-
	1416	+	carboxylate (BB-22),
1387	1417		d. naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3-
1388	1418		carboxylate (FDU-PB-22), or
1389	1419		e. naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-
1390	1420		carboxylate (NM2201);
1391	1421		11. Adamantanoylindoles: Any compound containing an
1392	1422		adamantanyl-(1H-indol-3-yl)methanone structure with or without
1393	1423		substitution at the nitrogen atom of the indole ring by an alkyl,
1394	1424		haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethy l,
1395	1425		benzyl, halobenzyl, 1 -(N-methyl-2-piperidinyl)methyl, 2 -(4-
1396	1426		morpholinyl)ethyl, 1 -(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3-
1397	1427		morpholinyl)methyl, ( tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
1398	1428		phenyl, or halophenyl group, whether or not further subst ituted in
1399	1429		the indole ring to any extent , and whether or not substituted in the
1400	1430		adamantyl ring to any extent. Adamantanoylindoles include, but are
1401	1431		not limited to:
1402		-	a. adamantan-1-yl[1-[(1-methyl-2-piperidinyl)methyl]-1H-
1403		-	indol-3-yl]methanone (AM1248), or
1404		-	b. adamantan-1-yl-(1-pentyl-1H-indol-3-yl)methanone (AB-
1405		-	001);
1406		-	12. Carbazole Ketone: Any compound containing (9H -carbazole-3-
1407		-	yl) methanone structure with or without substitution at the nitrogen
1408		-	atom of the carbazole ring by an alkyl, haloalkyl, cyanoalkyl,
1409		-	alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -
1410		-	(N-methyl-2-piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1 -(N-methyl-
1411	1432
1412		-	ENGR. S. B. NO. 860 Page 29 1
	1433	+	SENATE FLOOR VERSION - SB860 SFLR Page 29
	1434	+	(Bold face denotes Committee Amendments) 1
1413	1435		2
1414	1436		3
1415	1437		4
1416	1438		5
1417	1439		6
1418	1440		7
1419	1441		8
1420	1442		9
1421	1443		10
1422	1444		11
1423	1445		12
1424	1446		13
1425	1447		14
1426	1448		15
1427	1449		16
1428	1450		17
1429	1451		18
1430	1452		19
1431	1453		20
1432	1454		21
1433	1455		22
1434	1456		23
1435	1457		24
1436	1458
	1459	+	a. adamantan-1-yl[1-[(1-methyl-2-piperidinyl)methyl]-1H-
	1460	+	indol-3-yl]methanone (AM1248), or
	1461	+	b. adamantan-1-yl-(1-pentyl-1H-indol-3-yl)methanone (AB-
	1462	+	001);
	1463	+	12. Carbazole Ketone: Any compound containing (9H -carbazole-3-
	1464	+	yl) methanone structure with or without substitution at the nitrogen
	1465	+	atom of the carbazole ring by an alkyl, haloalkyl, cyanoalkyl,
	1466	+	alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -
	1467	+	(N-methyl-2-piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1 -(N-methyl-
1437	1468		2-pyrrolidinyl)methyl, 1 -(N-methyl-3-morpholinyl)methyl,
1438	1469		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
1439	1470		halophenyl group, with substitution at the carbon of the methanone
1440	1471		group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
1441	1472		cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
1442	1473		1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
1443	1474		dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
1444	1475		further substituted at the carbazole, adamantyl, naphthyl, phenyl,
1445	1476		pyrrole, quinolinyl, or cycloalkyl rings to any extent. Carbazole
1446	1477		Ketones include, but are not limited to, naphthalen -1-yl(9-pentyl-
1447	1478		9H-carbazol-3-yl)methanone (EG-018);
1448	1479		13. Benzimidazole Ketone: Any compound containing
1449	1480		(benzimidazole-2-yl) methanone structure with or without
1450	1481		substitution at either nitrogen atom of the benzimidazole ring by an
1451	1482		alkyl, haloalkyl, cyanoalkyl, alkeny l, cycloalkylmethyl,
1452		-	cycloalkylethyl, benzyl, halobenzyl, 1 -(N-methyl-2-
1453		-	piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1 -(N-methyl-2-
1454		-	pyrrolidinyl)methyl, 1 -(N-methyl-3-morpholinyl)methyl,
1455		-	(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
1456		-	halophenyl group, with substitution at the carbon of the methanone
1457		-	group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
1458		-	cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
1459		-	1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
1460		-	dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
1461	1483
1462		-	ENGR. S. B. NO. 860 Page 30 1
	1484	+	SENATE FLOOR VERSION - SB860 SFLR Page 30
	1485	+	(Bold face denotes Committee Amendments) 1
1463	1486		2
1464	1487		3
1465	1488		4
1466	1489		5
1467	1490		6
1468	1491		7
1469	1492		8
1470	1493		9
1471	1494		10
1472	1495		11
1473	1496		12
1474	1497		13
1475	1498		14
1476	1499		15
1477	1500		16
1478	1501		17
1479	1502		18
1480	1503		19
1481	1504		20
1482	1505		21
1483	1506		22
1484	1507		23
1485	1508		24
1486	1509
	1510	+	cycloalkylethyl, benzyl, halobenzyl, 1 -(N-methyl-2-
	1511	+	piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1 -(N-methyl-2-
	1512	+	pyrrolidinyl)methyl, 1 -(N-methyl-3-morpholinyl)methyl,
	1513	+	(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
	1514	+	halophenyl group, with substitution at the carbon of the methanone
	1515	+	group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
	1516	+	cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
	1517	+	1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
	1518	+	dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
1487	1519		further substituted in the benzimidazole, adamantyl, naphthyl,
1488	1520		phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent.
1489	1521		Benzimidazole Ketones include, but are not limited to:
1490	1522		a. naphthalen-1-yl(1-pentyl-1H-benzo[d]imidazol-2-
1491	1523		l)methanone (JWH-018 benzimidazole analog), or
1492	1524		b. (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-
1493	1525		yl)(naphthalen-1-yl)methanone (FUBIMINA); and
1494	1526		14. Modified by Replacement: any compound defined in this
1495	1527		subsection that is modifi ed by replacement of a carbon with nitrogen
1496	1528		in the indole, naphthyl, indene, benzimidazole, or carbazole ring.
1497	1529		H. Any material, compound, mixture, extract, or preparation
1498	1530		that contains a prohibited kratom product as provided in paragraphs
1499	1531		3 and 4 of subsection A of Section 1 -1432.4 of this title.
1500	1532		I. Any prescription drug approved by the federal Food and Drug
1501	1533		Administration under the provisions of Sectio n 505 of the Federal
1502		-	Food, Drug, and Cosmetic Act, Title 21 of the United States Code,
1503		-	Section 355, that is des ignated, rescheduled , or deleted as a
1504		-	controlled substance under federal law by the United States Drug
1505		-	Enforcement Administration shall be excluded from Schedule I and
1506		-	shall be prescribed, distributed, dispensed , or used in accordance
1507		-	with federal law upon the issuance of a notice, final rule , or
1508		-	interim final rule by the United States Drug Enforcement
1509		-	Administration designating, rescheduling , or deleting as a
1510		-	controlled substance such a drug product under federal law, unless
1511	1534
1512		-	ENGR. S. B. NO. 860 Page 31 1
	1535	+	SENATE FLOOR VERSION - SB860 SFLR Page 31
	1536	+	(Bold face denotes Committee Amendments) 1
1513	1537		2
1514	1538		3
1515	1539		4
1516	1540		5
1517	1541		6
1518	1542		7
1519	1543		8
1520	1544		9
1521	1545		10
1522	1546		11
1523	1547		12
1524	1548		13
1525	1549		14
1526	1550		15
1527	1551		16
1528	1552		17
1529	1553		18
1530	1554		19
1531	1555		20
1532	1556		21
1533	1557		22
1534	1558		23
1535	1559		24
1536	1560
	1561	+	Food, Drug, and Cosmetic Act, Title 21 of the United States Code,
	1562	+	Section 355, that is designated, rescheduled , or deleted as a
	1563	+	controlled substance under federal law by the United States Drug
	1564	+	Enforcement Administration shall be excluded from Schedule I and
	1565	+	shall be prescribed, distributed, dispensed , or used in accordance
	1566	+	with federal law upon the issuance of a notice, final rule , or
	1567	+	interim final rule by the United States Drug Enforcement
	1568	+	Administration designating, rescheduling , or deleting as a
	1569	+	controlled substance such a drug product under federal law, unless
1537	1570		and until the State Boar d of Pharmacy takes action pursuant to
1538	1571		Section 2-201 of this title. If the Board of Pharmacy does not take
1539	1572		action pursuant to Section 2 -201 of this title, the drug product
1540	1573		shall be deemed to be designated, rescheduled , or deleted as a
1541	1574		controlled substance in accordance with federal law and in
1542	1575		compliance with the Uniform Controlled Dangerous Substances Act.
1543	1576		SECTION 2. This act shall becom e effective November 1, 2025.
1544		-	Passed the Senate the 25th day of March, 2025.
1545		-
1546		-
1547		-
1548		-	Presiding Officer of the Sena te
1549		-
1550		-
1551		-	Passed the House of Representatives the ____ day of __________,
1552		-	2025.
1553		-
1554		-
1555		-
1556		-	Presiding Officer of the House
1557		-	of Representatives
1558		-
	1577	+	COMMITTEE REPORT BY: COMMITTEE ON PUBLIC SAFETY
	1578	+	March 4, 2025 - DO PASS AS AMENDED BY CS